Highnoon Laboratories Limited (PSX:HINOON)

Pakistan · Delayed Price · Currency is PKR

1,020.54

+17.26 (1.72%)

At close: Jul 10, 2026

-0.91% (1Y)

Market Cap	54.07B +6.3%
Revenue (ttm)	28.20B +10.5%
Net Income	4.22B +18.7%
EPS	79.68 +18.7%
Shares Out	52.98M
PE Ratio	12.81
Forward PE	12.36
Dividend	50.00 (4.98%)
Ex-Dividend Date	Apr 22, 2026

Volume	14,336
Open	1,000.01
Previous Close	1,003.28
Day's Range	1,000.01 - 1,040.00
52-Week Range	755.56 - 1,241.00
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiary, engages in the development, production, marketing, and distribution of pharmaceutical and allied consumer products in Pakistan, Afghanistan, the United Arab Emirates, Sri Lanka, France, Sudan, Cambodia, Kenya, Iraq, Dubai, Tanzania, and internationally. The company offers medicines in various drug forms and brands for allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynecology, pediatrics, respiratory, and urology therapeutic areas. It ... [Read more]

Industry Pharmaceuticals

Sector Healthcare

Founded 1984

Employees 2,563

Stock Exchange Pakistan Stock Exchange

Ticker Symbol HINOON

Full Company Profile

Financial Performance

In 2025, Highnoon Laboratories's revenue was 27.71 billion, an increase of 12.44% compared to the previous year's 24.64 billion. Earnings were 4.13 billion, an increase of 21.83%.

Financial Statements